BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32987034)

  • 21. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer.
    Ochoa AE; Choi W; Su X; Siefker-Radtke A; Czerniak B; Dinney C; McConkey DJ
    Oncotarget; 2016 Dec; 7(49):80164-80174. PubMed ID: 27845906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pseudoangiosarcomatous urothelial carcinoma of the urinary bladder.
    Paner GP; Cox RM; Richards K; Akki A; Gokden N; Lopez-Beltran A; Krausz T; McKenney JK; Steinberg GD
    Am J Surg Pathol; 2014 Sep; 38(9):1251-9. PubMed ID: 25133708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients.
    Moschini M; Shariat SF; Lucianò R; D'Andrea D; Foerster B; Abufaraj M; Bandini M; Dell'Oglio P; Damiano R; Salonia A; Montorsi F; Briganti A; Colombo R; Gallina A
    Clin Genitourin Cancer; 2017 Aug; 15(4):e603-e607. PubMed ID: 28040422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.
    Kim PH; Cha EK; Sfakianos JP; Iyer G; Zabor EC; Scott SN; Ostrovnaya I; Ramirez R; Sun A; Shah R; Yee AM; Reuter VE; Bajorin DF; Rosenberg JE; Schultz N; Berger MF; Al-Ahmadie HA; Solit DB; Bochner BH
    Eur Urol; 2015 Feb; 67(2):198-201. PubMed ID: 25092538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.
    Guo CC; Dadhania V; Zhang L; Majewski T; Bondaruk J; Sykulski M; Wronowska W; Gambin A; Wang Y; Zhang S; Fuentes-Mattei E; Kamat AM; Dinney C; Siefker-Radtke A; Choi W; Baggerly KA; McConkey D; Weinstein JN; Czerniak B
    Eur Urol; 2016 Oct; 70(4):611-620. PubMed ID: 26988609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive pathological assessment of histological subtypes, molecular subtypes based on immunohistochemistry, and tumor-associated immune cell status in muscle-invasive bladder cancer.
    Ikeda J; Ohe C; Yoshida T; Kuroda N; Saito R; Kinoshita H; Tsuta K; Matsuda T
    Pathol Int; 2021 Mar; 71(3):173-182. PubMed ID: 33503295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.
    Choi W; Czerniak B; Ochoa A; Su X; Siefker-Radtke A; Dinney C; McConkey DJ
    Nat Rev Urol; 2014 Jul; 11(7):400-10. PubMed ID: 24960601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Subtypes of Bladder Cancer.
    McConkey DJ; Choi W
    Curr Oncol Rep; 2018 Aug; 20(10):77. PubMed ID: 30128829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy.
    Klatte T; Seitz C; Rink M; Rouprêt M; Xylinas E; Karakiewicz P; Susani M; Shariat SF
    J Urol; 2015 Nov; 194(5):1456-62. PubMed ID: 26162296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA.
    Morera DS; Hasanali SL; Belew D; Ghosh S; Klaassen Z; Jordan AR; Wang J; Terris MK; Bollag RJ; Merseburger AS; Stenzl A; Soloway MS; Lokeshwar VB
    J Urol; 2020 Jan; 203(1):62-72. PubMed ID: 31112107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three-antibody classifier for muscle invasive urothelial carcinoma and its correlation with p53 expression.
    Olkhov-Mitsel E; Hodgson A; Liu SK; Vesprini D; Xu B; Downes MR
    J Clin Pathol; 2022 Nov; 75(11):766-771. PubMed ID: 34103388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transition between urothelial carcinoma in situ and non-invasive micropapillary carcinoma as a pivot connection between diverse morphologies of bladder carcinoma: a case report of urothelial carcinoma with villoglandular differentiation.
    Tajima S; Koda K
    Int J Clin Exp Pathol; 2015; 8(3):3288-93. PubMed ID: 26045854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene Expression Profiling of Muscle-Invasive Bladder Cancer With Secondary Variant Histology.
    de Jong JJ; Narayan VM; Cronican AA; Gupta S; van Leenders GJLH; Boormans JL; Gibb EA; Konety BR
    Am J Clin Pathol; 2021 Oct; 156(5):895-905. PubMed ID: 34157072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
    McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
    Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of prominent retraction clefts in invasive urothelial carcinoma.
    Shah TS; Kaag M; Raman JD; Chan W; Tran T; Kunchala S; Shuman L; DeGraff DJ; Chen G; Warrick JI
    Hum Pathol; 2017 Mar; 61():90-96. PubMed ID: 27818288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ARID1A alteration in aggressive urothelial carcinoma and variants of urothelial carcinoma.
    Li J; Lu S; Lombardo K; Monahan R; Amin A
    Hum Pathol; 2016 Sep; 55():17-23. PubMed ID: 27137986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between immunohistochemical expression of Ki-67and P63 and aggressiveness of urinary bladder urothelial carcinoma.
    Abdallah MM; Wahbbah MA; Selem M; Abdou AG; Sultan SM
    J Immunoassay Immunochem; 2021 Mar; 42(2):188-201. PubMed ID: 33206579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy.
    Martini T; Heinkele J; Mayr R; Weis CA; Wezel F; Wahby S; Eckstein M; Schnöller T; Breyer J; Wirtz R; Ritter M; Bolenz C; Erben P
    Urol Oncol; 2018 Dec; 36(12):530.e19-530.e27. PubMed ID: 30446441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary bladder carcinoma with divergent differentiation featuring small cell carcinoma, sarcomatoid carcinoma, and liposarcomatous component.
    Yasui M; Morikawa T; Nakagawa T; Miyakawa J; Maeda D; Homma Y; Fukayama M
    Pathol Res Pract; 2016 Sep; 212(9):833-7. PubMed ID: 27461832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.